1. FDA Blood Products Advisory Committee 62nd Meeting, Bethesda, Maryland, March 26, 1999. Transcript, Miller Reporting Company, Inc. http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3504t2.pdf .
2. FDA Blood Products Advisory Committee 65th Meeting, Silver Spring, Maryland, March 17, 2000 Transcript, Miller Reporting Company, Inc. http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3603t2a.pdf .
3. FDA/CBER. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency, 2005. http://www.fda.gov/OHRMS/DOCKETS/98fr/2005D-0438-gdl0001.pdf .
4. FDA/CBER. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency, 2008. http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm078526.pdf .
5. Behring EA, Kitasato S. Über das zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.